8-K: CEL-SCI Corporation Prices $7.2M Public Offering

CEL-SCI Corporation announced the pricing of a public offering of 6,000,000 shares of common stock at $1.20 per share, raising approximately $7.2 million in gross proceeds.

Summary

• CEL-SCI Corporation has successfully priced a public offering of 6,000,000 shares of its common stock.
• The offering price was set at $1.20 per share.
• The gross proceeds from this offering are approximately $7.2 million, before deducting fees and expenses.
• The offering closed on May 13, 2026.
• Net proceeds will be used for the continued development of Multikine, general corporate purposes, and working capital.
• The securities were offered under an effective registration statement on Form S-1, declared effective on May 11, 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive development, as the capital raise was successfully executed, providing necessary funds for development, but the offering price and the company's clinical-stage status present ongoing risks.

Positives

• Successful completion of a public offering, raising $7.2 million in gross proceeds.
• The offering was priced at $1.20 per share, indicating investor interest at this valuation.
• Proceeds are earmarked for the development of Multikine, a key company asset.
• The offering closed promptly on May 13, 2026, demonstrating efficient execution.

Negatives

• The company is still in the clinical stage, with Multikine not yet approved for sale.
• Significant reliance on future capital raises to fund operations and development.
• The offering price of $1.20 per share may reflect a lower valuation than desired by some investors.

Risks

• Inability to duplicate clinical results demonstrated in studies.
• Timely development of potential products that can be shown to be safe and effective.
• Receiving necessary regulatory approvals.
• Difficulties in manufacturing potential products.
• Inability to raise necessary capital.
• Risks detailed in the company's Form 10-K for the year ended September 30, 2025.

Future Outlook

The company intends to use the net proceeds from the offering to fund the continued development of Multikine, for general corporate purposes, and working capital. Forward-looking statements indicate potential risks and uncertainties that could cause actual results to differ materially from projections.

Management Comments

• CEL-SCI believes that boosting a patient's immune system before surgery, radiotherapy and chemotherapy have damaged it, should provide the greatest possible impact on survival.
• Multikine is designed to help the immune system 'target' the tumor at a time when the immune system is still relatively intact and thereby thought to be better able to mount an attack on the tumor.

Industry Context

StockSavvy.ai notes that this capital raise by CEL-SCI, a clinical-stage cancer immunotherapy company, is crucial for advancing its lead candidate, Multikine. Such offerings are common for biotech firms requiring significant funding for clinical trials and regulatory processes, especially in a competitive landscape where successful drug development and regulatory approval are paramount.

Stakeholder Impact

• Shareholders: Dilution from the issuance of new shares, but also potential for future value if Multikine development is successful.
• Employees: Continued funding for operations and development, potentially securing job stability.
• Creditors: Improved working capital may enhance the company's ability to meet its financial obligations.

Next Steps

• Continue development of Multikine.
• Utilize net proceeds for general corporate purposes and working capital.

Key Dates

Recommendation

The successful capital raise provides essential funding for continued development of Multikine, which is a positive. However, the company remains in the clinical stage with significant regulatory and development risks. The current share price reflects these uncertainties, making 'hold' appropriate pending further clinical and regulatory progress.

Keywords

CEL-SCI Corporation, CVM, Public Offering, Common Stock, Multikine, Cancer Immunotherapy, Clinical Stage, SEC Filing